CymaBay Therapeutics, Inc.
(NASDAQ : CBAY)

( )
CBAY After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
VTLVital Therapies, Inc.
1.50%13.513.3%$792.68m
AMGNAmgen Inc.
0.97%206.001.3%$773.44m
GILDGilead Sciences, Inc.
1.54%64.110.9%$388.34m
CELGCelgene Corporation
0.51%95.221.3%$348.72m
BIIBBiogen Inc.
1.74%235.721.3%$309.32m
ILMNIllumina, Inc.
0.87%288.653.5%$303.84m
VRTXVertex Pharmaceuticals Incorporated
1.16%187.091.9%$267.03m
ALXNAlexion Pharmaceuticals, Inc.
1.65%112.682.0%$250.97m
EXASExact Sciences Corporation
-1.39%118.1624.1%$248.01m
REGNRegeneron Pharmaceuticals, Inc.
0.52%298.382.6%$217.05m
AAgilent Technologies, Inc.
0.96%71.761.6%$206.55m
SRPTSarepta Therapeutics, Inc.
-3.71%120.3114.7%$153.85m
INCYIncyte Corporation
1.68%84.522.5%$100.26m
BMRNBioMarin Pharmaceutical Inc.
1.19%77.414.3%$94.71m
GHDXGenomic Health, Inc.
-0.56%74.221.8%$90.42m

Company Profile

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.